Immunovant (IMVT) Cash from Financing Activities (2019 - 2026)

Immunovant has reported Cash from Financing Activities for 8 years, with the latest figure at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 99.19% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $595.8 million (up 31.08% YoY), and the FY2026 full-year result was $595.8 million, up 31.08% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $3.6 million, down from $564.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $564.6 million in Q4 2025, with the low at $21000.0 in Q2 2022.
• Historically, Cash from Financing Activities has averaged $106.2 million across 5 years, with a median of $2.5 million in 2024.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities sank 99.48% — and 2025, when it soared 29065.83%.
• Immunovant's Cash from Financing Activities stood at $70.6 million in 2022, then jumped by 565.21% to $469.8 million in 2023, then slumped by 99.48% to $2.5 million in 2024, then jumped by 22814.08% to $564.6 million in 2025, then plunged by 99.36% to $3.6 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.6 million (Q1 2026), $564.6 million (Q4 2025), and $24.6 million (Q3 2025), per Business Quant data.